Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by prophetoffactzon Jun 05, 2023 7:16pm
98 Views
Post# 35481441

RE:RE:RE:RE:RE:The reality

RE:RE:RE:RE:RE:The reality
boazklinghorn wrote: Also dont forget that we burned 1.3 Million cash last quarter. It wasnt just a loss quarter it was a BIG loss. 



In its Year-End Financials CZO had recognized a defered tax liability of $1,095,986. Are you suggesting it shouldn't have paid taxes? 

Given the significant expenses CZO expects this year would you rather CZO report revenue this year as opposed to last year to minimize the tax bill this year? CZO built record inventory in Q4 helping reduce profit and added significant inventory in Q1 2023 too. With record inventory on hand and re-ordering expected to commence with the completion of the Aveeno and Neutrogena spin-out could CZO have a sigificant revenue surge in future quarters as it also has the surge in avenanthramide clinical trial costs, etc.? Could there be tax planning involved?

<< Previous
Bullboard Posts
Next >>